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The Q fever bacterium Coxiella burnetii replicates inside host cells
within a large Coxiella-containing vacuole (CCV) whose biogenesis
relies on the Dot/Icm-dependent secretion of bacterial effectors.
Several membrane trafficking pathways contribute membranes,
proteins, and lipids for CCV biogenesis. These include the endo-
cytic and autophagy pathways, which are characterized by phos-
phatidylinositol 3-phosphate [PI(3)P]-positive membranes. Here
we show that the C. burnetii secreted effector Coxiella vacuolar
protein B (CvpB) binds PI(3)P and phosphatidylserine (PS) on CCVs
and early endosomal compartments and perturbs the activity of
the phosphatidylinositol 5-kinase PIKfyve to manipulate PI(3)P me-
tabolism. CvpB association to early endosome triggers vacuolation
and clustering, leading to the channeling of large PI(3)P-positive
membranes to CCVs for vacuole expansion. At CCVs, CvpB binding
to early endosome- and autophagy-derived PI(3)P and the concom-
itant inhibition of PIKfyve favor the association of the autophago-
somal machinery to CCVs for optimal homotypic fusion of the
Coxiella-containing compartments. The importance of manipulat-
ing PI(3)P metabolism is highlighted by mutations in cvpB resulting
in a multivacuolar phenotype, rescuable by gene complementa-
tion, indicative of a defect in CCV biogenesis. Using the insect
model Galleria mellonella, we demonstrate the in vivo relevance
of defective CCV biogenesis by highlighting an attenuated viru-
lence phenotype associated with cvpB mutations.
Coxiella burnetii | host–pathogen interactions | phosphoinositides
The obligate intracellular bacterium Coxiella burnetii is respon-sible for severe outbreaks of the zoonosis Q fever (1). The pri-
mary targets of Coxiella are alveolar macrophages; however,
bacteria can invade phagocytic and nonphagocytic cells and
disseminate to other tissues and organs, such as the liver and
heart, giving rise to hepatitis and endocarditis (1). Because of its
remarkable infectivity and its environmental stability, Coxiella is
considered a category B biothreat (2). Upon internalization by
phagocytic and nonphagocytic cells, bacteria remain confined
within Coxiella-containing vacuoles (CCVs), tight-fitting com-
partments that mature along the endocytic pathway (1). Key to the
successful colonization of host cells is the acidification of CCVs,
which activates bacterial metabolism and effectors translocation
by a Dot/Icm type IV secretion system (3). Bioinformatics analysis
identified more than 300 Coxiella candidate effectors, a third of
which have been validated for secretion (1, 4). Many Coxiella ef-
fectors remain poorly understood or completely uncharacterized,
but it is clear that several of these manipulate host vesicular
trafficking, allowing CCVs to intercept and recruit membranes,
proteins, and lipids from the endocytic, autophagy, and recycling
pathways (4). SNAREs such as VAMP7 and Syntaxin-17 play a key
role in this process, mediating the fusion events that lead to the
biogenesis of large CCVs that occupy the majority of the host cell
cytoplasm (5, 6). Mature CCVs are dynamic acidic compartments
(pH 4.8), containing active hydrolases, which Coxiella is able to
resist, and are positive for markers of late endosomes, lysosomes,
and autophagosomes such as vATPase, LAMP1, CathepsinD, CD63,
and microtubule-associated protein 1A/1B-light chain 3 (LC3)
(7). Many efforts are being focused on the identification and
characterization of the Coxiella effectors involved in CCV bio-
genesis, as well as in the identification of the host cell trafficking
pathways hijacked by this microbe. It has recently been shown
that the Coxiella effector Coxiella vacuolar protein B (CvpB; also
referred to as Cig2) is required for CCV homotypic fusion, which
seems to be mediated by the autophagy machinery (8, 9).
However, the link between CvpB and autophagy remains to
be defined.
Phosphoinositides (PIs) are short-lived lipids whose spatio-
temporal localization is determined by the activity of specific ki-
nases and phosphatases (10). Their presence dictates the identity
of cellular organelles and allows the targeted recruitment and
activation of many downstream effectors, making them important
signaling hubs for the regulation of cellular functions, including
membrane traffic and actin rearrangement. In recent years, PIs
have emerged as new targets for a number of intracellular bac-
terial pathogens (11–13). As for all host/pathogen interactions, the
strategies developed by different pathogens to exploit host PIs are
extremely diverse. Bacterial effectors may use host PIs as anchors
to specific host cell membranes, whereas others have evolved to
manipulate their metabolism directly by mimicking eukaryotic
kinases or phosphatases or indirectly by enhancing or blocking the
activity of host PI-metabolizing enzymes (11–13). The manipulation
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of PI metabolism has pleiotropic downstream effects, mediated by
the numerous PI effectors, which are collectively beneficial for
the establishment/development of infections.
Building on our recent screen of a Coxiella transposon library
(14, 15), here we use image-based supervised machine learning
to address the mechanisms regulating the fusogenicity of CCVs.
We show that the Coxiella effector CvpB localizes at CCVs
and early endosomes by interacting with phosphatidylinositol
3-phosphate [PI(3)P] and phosphatidylserine (PS). CvpB binding
to PI(3)P interferes with the recruitment of the phosphatidyli-
nositol 5-kinase PIKfyve at PI(3)P-positive compartments, thereby
preventing PI(3)P phosphorylation to PI(3,5)P2. This allows
CvpB to play a dual role in CCV biogenesis during infections. At
early endosomes, CvpB leads to the appearance of large PI(3)P-
positive compartments that interact and fuse with CCVs for
vacuole expansion. At CCVs, CvpB binding to PI(3)P incoming
from early endosomes and autophagosomes, and the concomi-
tant inhibition of PIKfyve, is essential to recruit and stabilize
components of the autophagy machinery to mediate CCV homo-
typic fusion. The significance of this process is highlighted by six
independent transposon insertions in cvpB resulting in a multi-
vacuolar phenotype, with Coxiella replicating within isolated
CCVs that fail to coalesce into a single vacuole. The cvpB::Tn
multivacuolar phenotype can be rescued by gene complementa-
tion or by inhibiting the phosphatidylinositol 5-kinase PIKfyve,
provided that the autophagy machinery is functional. Impor-
tantly, despite the lack of an intracellular replication phenotype,
cvpB mutation attenuates Coxiella virulence in the insect model
Galleria mellonella, demonstrating an important role of CCV
biogenesis for Coxiella pathogenesis.
Results
Identification of Coxiella Factors Involved in CCV Biogenesis Using
Image-Based Supervised Machine Learning. In the context of a
multiparametric high-content screen of a Coxiella transposon
mutant library, we have recently reported the seemingly multi-
vacuolar phenotype associated with a transposon insertion in the
dot/icm gene icmS (14). The Legionella pneumophila IcmS ho-
molog is a chaperone that mediates the translocation of specific
effectors (16, 17), suggesting that Coxiella IcmS may regulate the
translocation of effectors involved in the homotypic fusion of
CCVs. This phenotype was further investigated by challenging
Vero cells for 6 d with the Coxiella control transposon mutant
Tn1832 [which carries an intergenic transposon insertion and
phenocopies WT Coxiella (14)] or the icmS::Tn mutant and an-
alyzing the morphology of CCVs by fluorescence microscopy.
Cells infected with Tn1832 displayed large CCVs positive for the
lysosomal marker LAMP1 and the autophagosomal marker LC3
(SI Appendix, Fig. S1 A and B, Top). Conversely, Coxiella icmS::Tn
replicated within clusters of small LAMP1-positive, but LC3-
negative, compartments (SI Appendix, Fig. S1 A and B, Bottom).
EM confirmed that cells infected with Tn1832 presented large
Coxiella-filled vacuoles (SI Appendix, Fig. S1C, Left), as opposed
to icmS::Tn-infected cells (SI Appendix, Fig. S1C, Right), which
presented several tight-fitting vacuoles enclosing few bacteria.
To determine whether the multivacuolar phenotype results from
the defective secretion of Coxiella effectors involved in CCV
homotypic fusion, we used image-based supervised machine
learning to mine the database generated during the screen of our
Coxiella transposon library (14) and identify transposon inser-
tions resulting in multivacuolar phenotypes. Among others, this
approach identified the icmS::Tn mutant as well as all six
transposon insertions in cvpB (CBU_0021; SI Appendix, Fig.
S2A) previously identified in our screen as affecting the size of
intracellular Coxiella colonies (14) and recently reported as im-
portant for the homotypic fusion of CCVs (8). The axenic and
intracellular replication of six independent cvpB transposon
mutants (Tn1146, Tn396, Tn239, Tn170, Tn2579, and Tn2032)
was thus analyzed. When inoculated in the axenic medium
acidified citrate cysteine medium-2 (ACCM-2) and allowed to
grow for 6 d, cvpB mutants replicated with kinetics comparable
to those of Tn1832 (SI Appendix, Fig. S2B). However, when used
to challenge epithelial cell lines (Vero, HeLa, U2OS, or A431),
cvpB mutants consistently displayed a marked multivacuolar
phenotype, with Coxiella replicating within clusters of three or
more LAMP1-positive CCVs (SI Appendix, Fig. S2C). The num-
ber and size of Coxiella CCVs within a cluster varied depending on
the cell line: Vero and A431 cells infected with the cvpB mutants
presented a higher number of relatively small CCVs; these were
fewer but larger in HeLa cells, and U2OS cells displayed an in-
termediate phenotype. More than 50% of cells infected with the
cvpB mutants presented a multivacuolar phenotype, regardless of
the cell line and of the multiplicity of infection (MOI) used for
infections (e.g., 100, 10, 1). As previously reported (8), the pres-
ence of multiple, average-sized CCVs in cells infected with the
cvpB transposon mutants did not impact the intracellular repli-
cation of Coxiella (SI Appendix, Fig. S2D). cvpB encodes an 809-aa
protein with a PmrA consensus sequence (18) 102 nt upstream of
the start codon and a putative E-block domain (19) at the C
terminus (SI Appendix, Fig. S2A). CvpB translocation was thus
assessed by using a β-lactamase secretion assay on U2OS cells
challenged with Coxiella for 24 and 48 h. β-Lactamase–tagged
CvpB was efficiently translocated at both time points (SI Appen-
dix, Fig. S3A). Conversely, CvpB translocation was abolished by
the deletion of its putative E-block or by a transposon insertion in
dotA (SI Appendix, Fig. S3A). The efficient expression of all
β-lactamase–tagged CvpB constructs was verified by Western blot
(SI Appendix, Fig. S3B). These observations are in agreement with
the recently reported translocation of CvpB (8, 9).
The Coxiella cvpB::Tn Mutant Is Attenuated in the in Vivo Model
G. mellonella. The in vivo relevance of the CvpB mutation was
investigated by using the insect model G. mellonella (20). Larvae
were injected in the upper right proleg with 106 genome equiv-
alents (GE)/mL of WT Coxiella, Tn1832, or the cvpB mutant
Tn1146, and the survival rate was determined over 10 d. Larvae
injected with PBS solution were used as controls. As previously
reported (14, 20), Galleria larvae were efficiently killed by WT
Coxiella or Tn1832; however, the injection of the cvpB mutant
strain resulted in the killing of 50% of the larvae over the same
time course (SI Appendix, Fig. S3C). Importantly, taking into
account the lack of obvious intracellular replication phenotypes
associated with cvpB mutations, this attenuation in virulence
speaks in favor of an important role of CCV biogenesis for
Coxiella pathogenesis. The bacterial load in infected larvae was
monitored at 96 and 120 h post injection by real-time PCR using
the Coxiella com1 gene. At both time points, Coxiella load within
infected larvae was significantly affected in the cvpB mutation
(SI Appendix, Fig. S3D).
CvpB Mediates Homotypic Fusion of CCVs and Vacuolation. As all six
transposon insertions in cvpB result in comparable phenotypes,
we focused our study on Tn1146, which carries the most up-
stream transposon insertion, 791 nt downstream of the starting
codon (14). Southern blot analysis validated the presence of a
single transposon insertion in Tn1146 (hereafter referred to as
cvpB::Tn; SI Appendix, Fig. S3E). The cvpB::Tn mutation was
complemented by using a mini-Tn7 transposon system to express
an HA-tagged copy of CvpB under the regulation of an anhy-
drotetracycline (aTc)-inducible promoter (cvpB::Tn-miniTn7:cvpB;
hereafter referred to as cvpB::Tn Comp.). Expression of CvpB by
the Coxiella complemented strain was assessed in the presence of
aTc by Western blot (SI Appendix, Fig. S3F). U2OS cells were
then challenged with the cvpB::Tn complemented strain in the
presence of aTc to trigger CvpB expression at the time of in-
fection. Expression of CvpB by cvpB::Tn Comp. restored the
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formation of single, large CCVs (SI Appendix, Fig. S2C). To
confirm that the multivacuolar phenotype was indeed caused by
an impairment of fusion between CCVs, U2OS cells were chal-
lenged with the control transposon mutant Tn1832 or the cvpB::Tn
mutant for 24 h and imaged over 36 h. CCV formation and
development was assessed by phase contrast, and Coxiella rep-
lication was monitored by using the GFP expressed by trans-
poson mutants. Cells infected with Coxiella Tn1832 displayed
large CCVs undergoing fission and fusion events, whereas cells
infected with the cvpB::Tn mutant gradually formed smaller
CCVs, which largely failed to coalesce into single CCVs over
time (Movie S1). Next, U2OS cells were challenged with the
cvpB::Tn complemented strain, and CvpB expression was trig-
gered at the time of infection or 72 h after infection. Induction of
CvpB at the moment of infection restored the formation of single,
large CCVs (Movie S1). Cells infected with the noninduced
complemented strain presented the typical multivacuolar
phenotype. This rapidly converted into a single CCV phenotype
upon induction of CvpB expression (Movie S2), clearly demon-
strating a role for CvpB in CCV homotypic fusion. Interestingly,
cells challenged with Tn1832 or the cvpB::Tn complemented
strains were characterized by the formation of large peripheral
vesicles, which migrated toward the forming CCV (Movie S1).
This was never observed in noninfected cells or in cells chal-
lenged with the cvpB::Tn strain, suggesting that CvpB favors
vacuolation (possibly of early endosomes), which may contribute
membranes to the forming CCV over the course of the infection.
CvpB Localizes at CCVs and Early Endosomes, Triggering Endosome
Enlargement and Clustering. To investigate the intracellular lo-
calization of CvpB, the cvpB::Tn mutation was complemented by
using a mini-Tn7 transposon system to express a 4xHA-tagged
copy of CvpB under the regulation of an aTc-inducible promoter
(cvpB::Tn 4xHAcvpB). The Coxiella dotA::Tn mutant (14) was
transformed with the same construct as negative control (dotA::Tn
4xHA-cvpB). U2OS cells were then challenged with the Coxiella
cvpB::Tn or dotA::Tn strains complemented with 4xHA-tagged
CvpB in the presence or absence of aTc. Cells were processed for
immunofluorescence at different time points postinfection, and
an anti-HA antibody was used to reveal the intracellular locali-
zation of CvpB. The translocated effector was more efficiently
observed at 24 h post infection and mainly labeled CCVs.
However, CvpB was also detected as spots scattered throughout
the cytoplasm of infected cells (Fig. 1A). Labeling was absent in
cells challenged with the noninduced cvpB::Tn 4xHAcvpB strain
or the induced dotA::Tn 4xHA-cvpB strain (Fig. 1A). The partic-
ular immunofluorescence protocol used to visualize 4xHA-CvpB
during infection did not allow the labeling of other intracellular
proteins. We thus optimized the codons in the cvpB ORF to
facilitate expression in eukaryotic cells and generated CvpB
constructs carrying HA, FLAG, or mCherry tags at the car-
boxyl-terminal end of the protein to visualize CvpB upon ec-
topic expression. Ectopically expressed CvpB decorated
LAMP1-positive CCVs in cells infected with the Coxiella trans-
poson mutant Tn1832 (Fig. 1B). Confirming our initial obser-
vations, CvpB also labeled vesicular structures clustered around
CCVs or scattered throughout the cytoplasm of infected cells
(Fig. 1B), which were LAMP1-negative. Membrane localization
was never observed when cells were transfected with plasmids
carrying the tags alone.
The nature of CvpB-labeled vesicles was then characterized in
noninfected cells. CvpB localized at large vacuolar structures as
well as peripheral clusters of smaller vesicles in U2OS cells
transfected with HA-FLAG or mCherry-tagged CvpB (Fig. 1C,
Left and Top Right). CvpB-HA–transfected U2OS cells were also
processed for immuno-EM and analyzed at the ultrastructural
level (Fig. 1C, Bottom Right), confirming CvpB localization at
large vacuoles and clusters of smaller vacuoles (Fig. 1C, Bottom
Middle). Ultrastructural analysis also revealed a clear plasma
membrane localization of CvpB that was elusive at the fluores-
cence level (Fig. 1C, Bottom Right). Immunogold labeling of
CvpB at the plasma membrane was concentrated at micro-
domains and membrane protrusions. Nontransfected or HA-
transfected cells did not present large vacuoles or clusters of
small vacuoles. The presence of markers of intracellular com-
partments at CvpB-induced vacuoles was then assessed. As
expected, CvpB-induced vesicles were negative for the lysosomal
marker LAMP1 (Fig. 2A). It has been suggested that CvpB may
be involved in recruiting autophagosomes to forming CCVs (8).
We therefore compared CvpB localization with that of the auto-
phagosomal marker LC3. U2OS cells transfected with CvpB-
mCherry and LC3C-GFP (Fig. 2B) or LC3B-GFP were mock
treated or incubated with chloroquine for 3 h before fixation.
CvpB was never found colocalizing with either autophagy marker
Fig. 1. CvpB localizes at host membranes in Coxiella-infected and non-
infected cells. (A) U2OS cells were challenged with cvpB::Tn 4xHAcvpB in the
presence (Left) or absence (Middle) of aTc or with dotA::Tn 4xHA-cvpB in the
presence of aTc (Right). Cells were fixed 24 h post infection, and translocated
CvpB was labeled by using an anti-HA antibody (red), bacteria were visual-
ized using GFP (green), and host cell nuclei were visualized using Hoechst
33258 (blue). (B) U2OS cells were infected for 3 d with Coxiella Tn1832 and
transfected with pLVX-CvpB-mCherry. At 12 h post transfection, cells were
fixed, and Coxiella colonies, CvpB, and LAMP1 were detected by using green
fluorescence (green), mCherry fluorescence (red), and anti-LAMP1 coupled
to Alexa Fluor 647 (blue), respectively. White arrows indicate discrete re-
gions of the Coxiella vacuole where CvpB and LAMP1 colocalize. (C, Left and
Top Right) U2OS cells transiently transfected with pLVX-CvpB-mCherry
(green) were fixed and labeled with Hoechst 33258 (blue). CvpB is found on
large vacuolar structures (1), tubules (2), and peripheral clusters of smaller
vesicles (3). (Insets) Images shown converted to inverted grayscale. (C, Bot-
tom Right) U2OS cells transiently transfected with CvpB-HA were fixed and
processed for immuno-EM with the HA tag labeled using Nanogold particles.
CvpB could be detected in clusters of small vesicles (arrow), enlarged vesicles
(filled arrow), or plasma membrane protrusions (arrowheads). (Scale bars:
A–C, Left and Top Right, 10 μm; C, Bottom Right, 1 μm).
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in any of the aforementioned conditions (Fig. 2B). On the con-
trary, CvpB vesicles were positive for the early endosomal
markers EEA1 (Fig. 2C), Rab5 (Fig. 2D), and the PI(3)P probe
GFP-2xFYVE (Fig. 2E). Of note, CvpB expression triggered a
significant increase in the size of early endosomes compared with
cells expressing mCherry alone (Fig. 2F). Late endosome and
autophagosome morphology was unaffected by CvpB expression
(Fig. 2F). These findings indicate that CvpB specifically targets
CCVs and early endosomal compartments and is capable of trig-
gering endosome swelling and clustering.
CvpB Binds PI(3)P and PS. The remarkable colocalization be-
tween CvpB and the 2xFYVE probe prompted us to determine
whether CvpB localization at CCVs and early endosomes might
be dictated by direct binding of PI(3)P on host cell membranes.
We thus generated a GST-tagged CvpB construct and used the
purified recombinant protein in a PIP Strip assay (Fig. 3A).
Purified GST was used as a control and did not interact with any
lipid spotted on the PIP Strips (SI Appendix, Fig. S3G). Con-
versely, GST-CvpB bound to monophosphorylated PIs [with a
preferential binding to PI(3)P] and with PS (Fig. 3A). CvpB
binding to PIs was further analyzed by using a PIP array, which
confirmed the preferential binding of the Coxiella effector to
PI(3)P (Fig. 3B). CvpB binding to PI(3)P was consistent with the
colocalization between CvpB and the PI(3)P probe GFP-
2xFYVE, whereas the binding to PS was unexpected. U2OS cells
were thus cotransfected with CvpB-mCherry and the GFP-tagged
C2 domain of lactadherin (GFP-Lact-C2), a specific PS probe. In-
deed, CvpB colocalized with the majority of intracellular structures
labeled by GFP-Lact-C2 (SI Appendix, Fig. S4A). CvpB binding to
PS and PI(3)P was then validated by using an in vitro cosedi-
mentation assay in which histidine-tagged CvpB was incubated with
large unilamellar vesicles (LUVs) of lipid composition matching
those found on PIP Strips at concentrations compatible with those
observed in intracellular vesicles (21). In agreement with our ob-
servations using PIP Strips, CvpB did not associate with LUVs
containing 100% phosphatidylcholine (PC; Fig. 3C). CvpB in-
teraction with LUVs was triggered by the combination of 30% PS
and 70% PC or 2% PI(3)P and 98% PC at LUVs membranes, and
was seemingly enhanced by a mixture of 68% PC, 30% PS, and 2%
PI(3)P (Fig. 3C).
Bioinformatics analysis failed to highlight known lipid-binding
domains for CvpB; thus, a mutational analysis of CvpB-mCherry
was carried out to identify the domain(s) required for its re-
cruitment on host cell membranes. Incremental C-terminal dele-
tions up to 500 aa of CvpB did not affect the protein colocalization
with FYVE-, Rab5-, and EEA1-positive vesicles (Fig. 3D and SI
Appendix, Fig. S5). Further C-terminal deletions completely delo-
calized CvpB to the cytoplasm (Fig. 3D and SI Appendix, Fig.
S5). Next, incremental deletions from the N terminus of CvpB
were generated. The deletion of the first 100 aa was sufficient to
delocalize CvpB to the cytoplasm of transfected cells (Fig. 3D
and SI Appendix, Fig. S5), indicating that the membrane-binding
domain (MBD) of CvpB is encompassed between amino acids 1
and 500 (Fig. 3D). Of note, despite CvpB1–500 colocalization with
early endosomal markers, cells transfected with CvpB1–500 dis-
played an attenuated vacuolation phenotype (Fig. 3D and SI
Appendix, Fig. S5), suggesting that the C-terminal domain of the
protein plays a role in membrane trafficking. In vitro cosedi-
mentation assay with LUVs confirmed these observations. Histidine-
tagged CvpB1–500 displayed a binding profile comparable to that of
the full-length protein, whereas CvpB500–809 did not associate to
LUVs, regardless of their lipid composition (Fig. 3C).
Fig. 2. CvpB colocalizes with early endosome markers triggering their
clustering and enlargement. U2OS (A–D) or U2OS GFP-2xFYVE (E) transiently
transfected with pLVX-CvpB-mCherry (red) and LC3C-GFP (B) were fixed and
labeled with anti-LAMP1 (A), anti-EEA1 (C), or anti-Rab5 (D) coupled to
Alexa Fluor 488 (green). (Scale bars: 10 μm.) (F) The median area of 100
vesicles was calculated in cells transfected with pLVX-mCherry (Ctrl) or pLVX-
CvpB-mCherry (CvpB) and in cells infected with Coxiella Tn1832, the cvpB::Tn
mutant, or its complemented strain (cvpB::Tn C.; ***P < 0.0001, *P < 0.05; ns,
not significant, one-way ANOVA, Bonferroni’s multiple comparison test).
Fig. 3. CvpB interacts with PI3P and PS via its N-terminal domain. Repre-
sentative protein/lipid overlay assays performed, incubating GST-CvpB with
PIP Strips (A), whereby several lipids are spotted at 100 pmol per spot, or
with PIP Arrays (B), whereby PIs are spotted at decreasing concentrations.
(C) Representative Western blot of cosedimentation assays in which histi-
dine-tagged CvpB (His-CvpB), its 1–500-aa N-terminal domain (His-CvpB1–500), or
its 500–809-aa C-terminal domain (His-CvpB500–809) were incubated with
LUVs containing 100% PC, 70% PC and 30% PS (PC/PS), 98% PC and 2% PI(3)P
[PC/PI(3)P], or 68% PC, 30% PS, and 2% PI(3)P [PC/PS/PI(3)P]. Following LUV
centrifugation, anti-Histidine antibodies were used to detect CvpB in the
pellet (P; bound to LUVs) or the supernatant (SN; unbound to LUVs) fraction
of samples. (D, Left) Schematic representation of the CvpB fragments ec-
topically expressed as mCherry fusion proteins. (Right) U2OS GFP-2xFYVE
(green) cells were transiently transfected with pLVX-CvpB-mCherry (1–809)
or CvpB fragments cloned into pLVX-mCherry (red). (Scale bars: 10 μm.)
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CvpB Mediates PI(3)P Enrichment of CCVs. To investigate the role of
CvpB in CCV biogenesis with respect to its PI(3)P binding
property and the colocalization with early endosomal markers,
the morphology and dynamics of mCherry-2xFYVE or mCherry-
Rab5 were assessed in cells infected with the Coxiella control
mutant Tn1832, the cvpB::Tn mutant, or the cvpB::Tn com-
plemented strain. In line with our observations in cells ectopi-
cally expressing CvpB, cells infected with Coxiella Tn1832 or the
cvpB::Tn complemented strain presented large FYVE- and
Rab5-positive vesicles, compared with noninfected cells (Fig.
2F), which clustered around LAMP1-positive CCVs (Fig. 4 A
and C and SI Appendix, Fig. S6A). The size of FYVE- and Rab5-
positive compartments was unaltered in cells infected with the
cvpB::Tn mutant, compared with noninfected cells (Fig. 2F), and
vesicles were scattered through the cytoplasm of infected cells. In
all cases, Rab5 was largely excluded from lysosome-derived
CCVs (SI Appendix, Fig. S6A), indicating that, if early endosome/
CCV fusion occurred, early endosomal markers were likely
lost as a consequence of endosomal maturation. Interestingly,
however, the FYVE domain probe was clearly found colocalizing
with LAMP1 at CCVs in a CvpB-dependent manner (Fig. 4 A–C).
This observation suggests that CvpB may alter the metabolism of
incoming PI(3)P (either from the endocytic or the autophagy
pathways) at CCV membranes. The distribution of early endo-
somal markers with respect to CCVs was also investigated by using
cell fractionation. In line with our observations by fluorescence
microscopy, the endosomal markers Rab5 and EEA1 were ex-
cluded from fractions containing CCVs generated by Coxiella
Tn1832 and the cvpB::Tn mutant (SI Appendix, Fig. S6B). Frac-
tions containing CCVs from cells infected with the cvpB::Tn
complemented strain were mainly concentrated in one fraction,
which was also positive for Rab5 and EEA1 (SI Appendix, Fig.
S6B), suggesting that early endosomal markers can be found at
CCVs, and enrichment of CCVs in a single fraction may facilitate
their detection. However, the possibility that early endosomal
markers detected by cell fractionation may originate from vesicles
clustered around CCVs cannot be excluded. We then used 4D
microscopy to investigate the dynamics of CvpB-triggered PI(3)P-
positive vesicles in U2OS cells expressing mCherry-2xFYVE.
Live imaging confirmed the presence of large PI(3)P-positive
vesicles clustered at CCVs generated by the Coxiella control
transposon mutant Tn1832 or the cvpB::Tn complemented strain
(Fig. 4D and Movies S3 and S4). In addition, the FYVE probe
clearly defined the contour of CCVs under these conditions.
Surface rendering of the acquired time lapses revealed the pres-
ence of PI(3)P in large patches, which sometimes completely
covered the surface of CCVs (Fig. 4D and Movies S3 and S4). A
number of PI(3)P-positive tubules also emanated from CCVs and
interacted with bystander PI(3)P-positive vesicles, which were
captured and merged with CCVs (Fig. 4D and Movies S3 and S4).
Cells infected with the cvpB::Tn mutant presented regular-sized
PI(3)P-positive vesicles that did not interact with CCVs (Movie
S5). Importantly, these findings correlate with our initial obser-
vation of waves of large vesicles formed at the periphery of the cell
and migrating toward CCVs (Movie S1).
CvpB Modulates the Intracellular Levels of PI(3)P.Host PIs and their
metabolism are known targets of a number of bacterial patho-
gens; we thus investigated whether Coxiella uses CvpB to ma-
nipulate pathways controlled by PS and/or PI(3)P. Besides its
role as a signaling lipid during apoptosis, it has been reported
that PS plays an important role in retrograde traffic from the
plasma membrane to the Golgi complex (22). We therefore
transfected U2OS cells with mCherry or CvpB-mCherry and
monitored retrograde transport by incubating cells with 1 μg/mL
FITC-labeled Cholera toxin B subunit (CtxB). After 60 min in-
cubation on ice, cells were washed and CtxB was chased at 37 °C
for 30 and 60 min. Further confirming CvpB localization at early
endosomes, CtxB was observed partially localizing at CvpB-
positive compartments 30 min post internalization (SI Appendix,
Fig. S4B, Top). At later time points, however, CtxB trafficked to
the Golgi complex unperturbed (SI Appendix, Fig. S4B, Bottom)
in control and CvpB-expressing cells (SI Appendix, Fig. S4C).
We next focused on the interaction of CvpB with PI(3)P. This
key signaling phospholipid is primarily produced at the level of
early endosomes and autophagosomes by the phosphorylation of
phosphatidylinositol in position 3 of the inositol ring, mediated
by class II and III PI3Ks (10). U2OS cells expressing GFP-
2xFYVE were thus treated with the PI3Ks inhibitors LY294002,
Spautin-1, or 3-methyladenine (3-MA) to deplete the majority of
PI(3)P and monitor the effects of PI(3)P depletion on the in-
tracellular distribution of CvpB. Upon GFP-2xFYVE relocalization
to the cytoplasm, cells were transfected with mCherry alone or with
CvpB-mCherry. DMSO-treated cells were used as control. mCherry
alone was found in the cytoplasm of DMSO-treated or PI3Ks
inhibitor-treated cells (Fig. 5A), whereas CvpB-mCherry was observed
labeling large vacuoles and clusters of smaller vacuoles in DMSO-
treated cells (Fig. 5B, Top). Interestingly, when CvpB-mCherry was
expressed in PI(3)P-depleted cells, the bacterial effector was still
observed labeling the same vesicular structures as in control cells
Fig. 4. CvpB induces the presence of PI(3)P at CCV. U2OS mCherry-2xFYVE
cells were infected with Coxiella Tn1832 (A), the cvpB::Tn mutant (B), or the
complemented strain (C) for 3 d. Coxiella colonies, FYVE-positive vesicles,
and LAMP1 were detected by using GFP (green), mCherry (red), and an anti-
LAMP1 antibody coupled to Alexa Fluor 647 (blue), respectively. (D) Represen-
tative images from Movie S3 illustrating surface rendering of mCherry-2xFYVE
(red) surrounding Coxiella Tn1832 colonies (green). Filled arrows point at PI
(3)P-positive tubules connected with the CCV. Simple arrows follow a
representative fusion event between a large PI(3)P-positive vesicle and the
PI(3)P-enriched CCV (Movie S3). (Scale bars: A–C, 10 μm; D, 5 μm.)
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(Fig. 5B, Bottom and SI Appendix, Fig. S7). Surprisingly, these
vesicles were also labeled by GFP-2xFYVE, indicating the
presence of PI(3)P (Fig. 5B, Bottom and SI Appendix, Fig. S7).
The levels of intracellular PI(3)P were calculated as the ratio of
GFP-2xFYVE intensity between labeled compartments and the
cytoplasm, revealing that CvpB expression restored 60% of the
PI(3)P probe on endosomal membranes (Fig. 5C). The same
results were obtained in cells transfected with CvpB before PI(3)P
depletion. Our observations suggest that CvpB may influence the
metabolism of PI(3)P in cells infected by Coxiella.
CvpB Increases Intracellular Levels of PI(3)P by Perturbing the Activity
of the PI 5-Kinase PIKfyve. Increases in the intracellular levels of
PI(3)P may result from an increased PI3-kinase activity or an
inhibition of PI 5-kinase activity (10). However, the restoration
of PI(3)P upon CvpB expression in the presence of several PI3Ks
inhibitors seems to rule out the possibility that CvpB modulates
PI3Ks activity. By using an in vitro PI3-kinase activity assay, we
investigated the possibility that CvpB itself may act as a PI3-
kinase. In agreement with the lack of known PI3-kinase domains
in the sequence of CvpB, the Coxiella effector did not exhibit any
kinase activity compared with Vps34, used here as positive
control, regardless of the temperature used for the assay or the
protein concentration (Fig. 5D). We therefore tested the possi-
bility that CvpB perturbs the activity of the PI3 phosphate 5-kinase
PIKfyve, which phosphorylates PI(3)P in position 5 of the ino-
sitol ring to generate PI(3,5)P2 (10). Indeed, several studies
reported an increase of PI(3)P leading to vacuolation in cells
where the activity of PIKfyve has been perturbed (23–25). The
effects of PIKfyve inhibition on PI(3)P-positive endosomes were
then compared with those of CvpB overexpression. U2OS cells
expressing GFP-2xFYVE were incubated with the specific PIK-
fyve inhibitor YM201636 (25) or transfected with CvpB-mCherry.
In agreement with our hypothesis, PIKfyve inhibition phenocopied
the ectopic expression of CvpB (Fig. 5 E and F). We thus tested
whether inhibiting PIKfyve in cells pretreated with PI3K inhib-
itors restores PI(3)P on early endosomes, as observed with the
ectopic expression of CvpB. U2OS cells expressing GFP-2xFYVE
were treated with LY294002, Spautin-1, or 3-MA for 4 h. Upon
GFP-2xFYVE relocalization to the cytoplasm, the PIKfyve inhibitor
YM201636 was added to the culture medium (in the presence of
PI3Ks inhibitors). Indeed, the combined treatment of cells with
PI3Ks inhibitors and YM201636 restored PI(3)P on endosomal
membranes, as indicated by the reappearance of GFP-2xFYVE
on these compartments (Fig. 5 C and G). PIKfyve and CvpB are
both recruited at membranes by interacting with PI(3)P (26),
raising the possibility that CvpB perturbs PIKfyve activity by
interfering with its recruitment at early endosomes. U2OS cells
were transfected with GFP-PIKfyve in combination with mCherry,
CvpB-mCherry, CvpB100–809-mCherry, CvpB1–400-mCherry, and
CvpB1–500-mCherry. PIKfyve recruitment at membranes was then
measured as the number of GFP puncta in transfected cells for
each condition. As previously described, control cells presented a
large cytoplasmic pool of PIKfyve as well as a number of small
puncta, revealing the protein association with endosomal vesicles
(24, 27) (Fig. 6 A and D). The coexpression of PIKfyve with
CvpB, significantly reduced the number of GFP puncta (Fig. 6 B
and D), indicating that, indeed, CvpB perturbs PIKfyve associ-
ation with PI(3)P-positive vesicles. Accordingly, coexpression of
PIKfyve with CvpB MBD mutants restored membrane localiza-
tion of PIKfyve (Fig. 6D), indicating that membrane targeting of
CvpB is required for PIKfyve perturbation. Finally, coexpression
of PIKfyve with CvpB1–500-mCherry also restored PIKfyve lo-
calization at cell membranes, where it colocalized with CvpB
(Fig. 6 C and D), indicating that CvpB does not outcompete
PIKfyve for PI(3)P, and that the C terminus domain of CvpB is
involved in blocking PIKfyve access to early endosomes. This is
consistent with the attenuated vacuolation phenotype observed
with CvpB1–500-mCherry described in Fig. 3D.
PIKfyve Inhibition Favors the Recruitment of the Autophagy
Machinery to CCVs to Mediate Their Homotypic Fusion. Our obser-
vations raised the interesting hypothesis that CvpB perturbs
PIKfyve activity to enrich CCVs in PI(3)P for optimal vacuole
biogenesis. To test whether PIKfyve inhibition favors CCV bio-
genesis, U2OS cells were transfected with nontargeting or with
three independent PIKfyve-targeting siRNAs (SI Appendix, Fig.
S8A) before challenge with the Coxiella control transposon mu-
tant Tn1832 or the cvpB::Tn mutant. Five days postinfection,
cells were fixed and the morphology of CCVs labeled by LAMP1
was investigated. CCV development was remarkably enhanced
in PIKfyve-depleted cells, with LAMP1-positive vacuoles being
Fig. 5. Ectopic expression of CvpB or PIKfyve inhibition counters the effect
of PI 3-kinase inhibitors. U2OS GFP-2xFYVE cells were incubated with DMSO
(Top) or the PI3-kinase inhibitor LY294002 (Bottom) for 4 h and transfected
with pLVX-mCherry (A) or pLVX-CvpB-mCherry (B) for 12 h. The redistribution of
the GFP-2xFYVE probe into the cytoplasm was measured as the vesicle-to-
background signal ratio of GFP-2xFYVE from 20 treated cells for each condition
(C) (SI Appendix, Fig. S7). (D) The PI3-kinase activity of CvpB at 780 nM (light red
bars) or 1,560 nM (dark red bars) was measured at room temperature (RT) or
37 °C and compared with no-lipid (white bars) or no-enzyme (gray bars) con-
ditions as negative controls and purified Vps34 at 780 nM (light blue bars) or
1,560 nM (dark blue bars) as positive controls. (E) U2OS GFP-2xFYVE cells were
incubated with DMSO (control) or YM201636 for 4 h or transfected with pLVX-
CvpB-mCherry for 12 h. (F) The size of GFP-2xFYVE–positive vesicles in U2OS
GFP-2xFYVE cells treated as in D was calculated. (G) U2OS GFP-2xFYVE cells
were incubated with DMSO or the PI3-kinase inhibitor LY294002 for 4 h. The
PIKfyve inhibitor YM201636 was then added to cells treated with LY294002,
and cells were incubated for 4 h. Values in C and D are means ± SEM of triplicate
experiments (ns, nonsignificant; ***P < 0.0001, two-way ANOVA, Bonferroni’s
multiple comparison test). Values in F are calculated from 500 vesicles measured
for each condition (***P < 0.0001, one-way ANOVA). (Scale bars: 10 μm.)
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significantly larger than those developed by control cells infected
by Coxiella Tn1832 (Fig. 7 A and C). More importantly, the
number of cells infected with Coxiella cvpB::Tn presenting a
multivacuolar phenotype was largely reduced in PIKfyve-depleted
cells, with Coxiella cvpB::Tn replicating in large CCVs in-
distinguishable from those generated by Coxiella Tn1832 (Fig. 7 B
and C). As expected, the multivacuolar phenotype was still ob-
served in cells treated with scrambled siRNA sequences (Fig. 7 B
and C). PIKfyve depletion also restored LC3 labeling on the single
CCVs generated by the cvpB::Tn mutants (Fig. 7D), indicating
that PIKfyve inhibition and the concomitant increase in the levels
of PI(3)P are functional to the recruitment of the autophagosomal
machinery to CCVs. Next, we investigated whether the inhibition
of PIKfyve is capable of restoring the single CCV phenotype in-
dependently of the autophagy machinery. U2OS cells treated with
siRNAs targeting ATG5 or ATG7 (SI Appendix, Fig. S8B), alone
or in combination with siRNAs targeting PIKfyve, were chal-
lenged with Coxiella Tn1832 or the cvpB::Tn mutant and analyzed
5 d post infection for the presence of multiple CCVs per cell.
Inhibition of autophagy triggered the appearance of a multi-
vacuolar phenotype in cells infected with Coxiella Tn1832, as
previously described (6) (Fig. 7C). Importantly, the combined
inhibition of ATG proteins and PIKfyve failed to rescue the
multivacuolar phenotype triggered by the inhibition of autophagy
(Fig. 7C); however, the multiple CCVs per cell were larger,
compared with cells interfered for ATG proteins alone (Fig. 7C).
Accordingly, the same phenotype was observed in cells challenged
with the cvpB::Tn mutant, where PIKfyve depletion largely failed
to rescue the multivacuolar phenotype in absence of a functional
autophagy machinery (Fig. 7C). In these cells, the inhibition of
ATG5 or ATG7 alone had no impact on the multivacuolar phe-
notype triggered by the cvpB::Tnmutant (Fig. 7C), suggesting that
the CvpB-mediated inhibition of PIKfyve is a prerequisite for
CCV expansion and to prime CCV membranes for the recruitment
of the autophagy machinery. In turn, autophagy controls homotypic
fusion between CCVs. To further define the relative contribution of
the endocytic and autophagy pathway to CCV biogenesis with re-
spect to CvpB, U2OS cells treated with siRNAs targeting EEA1 or
Rab5 (SI Appendix, Fig. S8B), alone or in combination with PIK-
fyve, were challenged with Coxiella Tn1832 or the cvpB::Tn mutant
and analyzed 5 d post infection for the presence of multiple CCVs
per cell. The inhibition of EEA1 or Rab5 in cells infected with
Coxiella Tn1832 or the cvpB::Tn mutant significantly reduced the
size of CCVs, but had no effect on the number of CCVs per cell,
compared with cells treated with control siRNA sequences (Fig.
7C). The combined inhibition of PIKfyve and Rab5 failed to rescue
the size of CCVs; however, it partially rescued the multivacuolar
phenotype in cells challenged with the cvpB::Tn mutant (Fig. 7C).
Fig. 6. CvpB perturbs PIKfyve activity by interfering with its recruitment to
PI(3)P-positive membranes. U2OS cells were transfected with pGFP-PIKfyve
(PIKfyve-GFP) in combination with pLVX-mCherry (A), pLVX-CvpB-mCherry
(B), or pLVX-CvpB100–809-mCherry, pLVX-CvpB1–400-mCherry, and pLVX-CvpB1–500-
mCherry (C). pLVX-CvpB-mCherry(1–500) (red) and PIKfyve (green) are merged
in C to illustrate colocalization (arrows and Inset). (D) The number of PIK-
fyve-positive puncta (arrows) per cell was calculated by using ICY from 42
cells for each condition. Red bars indicate medians (***P < 0.0001; *P < 0.05;
ns, not significant, one-way ANOVA, Dunnett’s multiple comparison test).
(Scale bars: 10 μm.)
Fig. 7. CvpB-mediated inhibition of PIKfyve promotes homotypic fusion of
CCVs via autophagy. U2OS cells were treated with control siRNA (Left) or
siRNA targeting PIKfyve (Right) for 24 h before being challenged with
Coxiella Tn1832 (A) or the cvpB::Tn mutant (B) for 5 d. Cells were then fixed,
and LAMP1 and DNA were labeled by using an anti-LAMP1 antibody cou-
pled to Alexa Fluor 555 (red) or Hoechst 33258 (blue), respectively. Coxiella
colonies were detected by using green Fluorescence (green). (C) U2OS cells
transfected with the indicated siRNA sequences were challenged with
Coxiella Tn1832 (white bars) or the cvpB::Tn mutant (gray bars). The median
area of CCVs and the percentage of cells presenting a multivacuolar phe-
notype (CCVs per cell > 3) were calculated for each condition by using
CellProfiler. (D) The percentage of CCVs positive for LC3 in cells treated as in
A and B was assessed for each condition. Values are means ± SEM of trip-
licate experiments in which 200 CCVs or 200 cells were analyzed for each
condition (***P < 0.0001; **P < 0.01; *P < 0.05; ns, not significant, one-way
ANOVA, Bonferroni’s multiple comparison test). (Scale bars: 10 μm.)
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Unfortunately, cells did not survive the combined inhibition of
EEA1 and PIKfyve. These observations indicate that the endocytic
pathway is mainly involved in the initial expansion of CCVs,
whereas the autophagy pathway mediates CCV homotypic fusion as
previously reported (6).
Discussion
One of the key features of CCVs is their remarkable fusogenicity,
which allows these compartments to intercept and merge with the
endocytic, autophagy, secretory, and recycling pathways (28–30). To
date, however, little is known about the mechanisms responsible for
CCV biogenesis as well as the protein and lipid composition of
CCVs. In this study, we addressed the fusogenicity of Coxiella
CCVs, first by describing the multivacuolar phenotype associated
with a transposon insertion in the Dot/Icm chaperone IcmS. By
using image-based supervised machine learning, we identify Coxiella
candidate effectors regulating homotypic fusion between CCVs.
We have thus identified six independent transposon insertions in
cvpB, which conferred a multivacuolar phenotype, rescuable by
gene complementation. CvpB has been recently identified as a Dot/
Icm effector that localizes at CCVs and plays a role in the in-
tracellular development of Coxiella (8, 9, 14). A parallel screen of a
Coxiella transposon library also highlighted the emergence of a
multivacuolar phenotype triggered by mutations in cvpB (8). The
absence of detectable amounts of LC3 on CCVs generated by the
cvpB mutant suggested a link between CvpB, autophagy, and
homotypic fusion between CCVs (8).
By using live imaging in combination with an inducible com-
plementation system, we demonstrate that the multivacuolar
phenotype associated with cvpB mutations is indeed a result of
impaired fusion between CCVs. Importantly, by using the insect
model G. mellonella, we show that, regardless of the lack of in-
tracellular replication phenotypes observed in cells infected with
the Coxiella cvpB::Tn mutants, defective CCV biogenesis has in
vivo relevance. Intrigued by the remarkable colocalization be-
tween CvpB and FYVE domain, a well-established probe for PI
(3)P, we used PIP Strip and in vitro cosedimentation with LUV
assays to show that the N-terminal domain encompassed be-
tween amino acids 1 and 500 allows CvpB binding to PI(3)P- and
PS-containing membranes, which is essential to target CvpB to
early endosomes. The reported intracellular distribution of PI(3)P
on early endosomal membranes and that of PS at the plasma
membrane and early endosomes correlated with our results on
the subcellular localization of CvpB. Interestingly, ectopically
expressed CvpB showed a differential localization in infected vs.
noninfected cells. In the absence of infection, CvpB localizes at
early endosomes and is excluded from LAMP1-positive lyso-
somes and autophagosomes, despite the latter sharing a similar
lipid composition with early endosomes. On the contrary, in in-
fected cells, the majority of CvpB is recruited to the LAMP1-
positive CCV, suggestive of the presence of PI(3)P and/or PS at
CCVs. Indeed, we report an unexpected PI(3)P enrichment of
Coxiella CCVs, which were thus far believed to have mainly ly-
sosomal characteristics. Other early endosomal markers such as
EEA1 and Rab5 remain largely undetected at CCVs.
PIs are key players in the regulation of eukaryotic signal trans-
duction, cytoskeleton architecture, and membrane trafficking (10).
Specific kinases and phosphatases control their spatial and temporal
distribution, allowing a precise and local modulation of essential
processes including endocytosis and phagocytosis, membrane
traffic, and autophagy (31–33). These processes are commonly
manipulated by bacterial pathogens to invade, survive, and rep-
licate within host cells. It is therefore not surprising that PIs and
their metabolism have emerged as the target of a growing
number of bacterial pathogens (11–13). Bacterial effectors can
bind PIs for membrane targeting (34) or acting on PI metabo-
lism, either by means of eukaryotic-like kinases and phospha-
tases secreted by the pathogen or by modulating the recruitment
of host PI-metabolizing enzymes (11, 12). Intravacuolar patho-
gens subvert PI metabolism to manipulate the lipid profile of
their host-derived replicative niche, thus controlling the inter-
actions with the endosomal maturation pathway according to
their needs. Mycobacterium tuberculosis (35, 36) and Legionella
pneumophila (37, 38) use effectors to deplete PI(3)P at the
surface of their vacuoles to block phagosomal maturation and
avoid fusion with degradative compartments. On the contrary,
Salmonella enterica serovar Typhimurium uses the SPI-1 sub-
strate SopB to maintain elevated levels of PI(3)P at the surface
of Salmonella-containing vacuoles, favoring their biogenesis (39–41).
Based on previous reports, the main source of PI(3)P-positive
membranes for CCVs are early endosomes and autophagosomes
(4). However, PI(3)P at late endosomes/lysosomes is expected to
be further phosphorylated to PI(3,5)P2, by the activity of the PI
5-kinase PIKfyve. Similarly to Legionella effectors, CvpB uses PIs
for membrane anchoring, apparently using a nonconventional
lipid-binding domain as previously reported for the Legionella
effectors SidC and SidM (42, 43). Similarly to the Salmonella
effector SopB, Coxiella CvpB triggers an increase in PI(3)P levels
of infected cells to favor the biogenesis of a spacious replicative
compartment (40). CvpB, however, does not possess PI3-kinase
activity. Instead, it uses its C-terminal domain to perturb the
recruitment of the PI 5-kinase PIKfyve at PI(3)P-positive
membranes, thereby interfering with its function and preserving
PI(3)P at CCVs. Whether this occurs by steric hindrance or by a
yet unidentified catalytic activity of the C-terminal domain of
CvpB remains to be elucidated. Accordingly, it has been reported
that the genetic, siRNA, or pharmacological-mediated inhibition
of PIKfyve is accompanied by an increase in PI(3)P (23–25).
PIKfyve inhibition has an important impact on endosomal mat-
uration (23, 24, 44, 45), retrograde traffic (46), and autophagy
(47, 48), which collectively result in the formation of large, late
endosomal compartments in which the autophagosomal marker
LC3 accumulates as a result of the defective fusion with ly-
sosomes. These features are also shared by Coxiella CCVs.
Accordingly, inhibition of PIKfyve phenocopied the ectopic
expression of CvpB, and the depletion of PIKfyve rescued the
multivacuolar phenotype in cells infected with the Coxiella cvpB::Tn
mutant, restoring the formation of large CCVs positive for LAMP1
and LC3.
PI(3)P generated by the autophagy-associated class III PI3-
kinase Vps34 is a master regulator of autophagy (49–51), and the
PI3-kinase inhibitors used in this study are also commonly used
autophagy inhibitors. A significant proportion of CCVs are
positive for LC3, indicating that the Coxiella replicative com-
partment intersects the autophagy pathway during maturation.
Rather than stimulating autophagy, however, Coxiella infections
seem to perturb its flux, similarly to what has been described for
PIKfyve inhibition (8, 47, 52). The emergence of multivacuolar
phenotypes when Coxiella-infected cells are silenced for ATG5,
ATG12, and the autophagy SNARE Syntaxin-17 (6, 8) demon-
strates an important role of autophagy in the homotypic fusion
between CCVs. As previously reported (8), we confirm here that
Coxiella cvpB mutants generate LC3-deficient CCVs. However,
the connection between CvpB and the autophagy machinery
remained to be defined. CvpB and LC3 localization at distinct
intracellular compartments in noninfected cells seems to rule out
a direct interaction between CvpB and autophagosomes. In-
terestingly, however, the presence of LC3 on CCVs generated by
the cvpB::Tn mutant is rescued, together with the single CCV
morphology, by gene complementation or by PIKfyve silencing,
indicating that the CvpB-mediated inhibition of PIKfyve is the
link between the Coxiella effector and the autophagy machinery
during CCV biogenesis. PIKfyve inhibition by CvpB, and the
concomitant presence of PI(3)P at CCVs, may contribute to
stabilize preexisting LC3 at the surface of Coxiella vacuoles.
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Alternatively, other Coxiella effectors may act in response to
CvpB to recruit LC3 to CCVs.
In summary, here we show that, similarly to other intracellular
bacterial pathogens, Coxiella uses effectors to manipulate PI
metabolism during infection. Upon translocation, CvpB asso-
ciates with CCVs and early endosomes by interacting with PI(3)P
and PS. There, CvpB exerts a dual function by interfering with
the activity of the PI 5-kinase PIKfyve to trigger an increase in
the levels of PI(3)P at specific subcellular compartments. At
early endosomes, this triggers vacuolation and clustering, which
may enhance the delivery of membranes, proteins, and lipids to
CCVs for optimal expansion. At CCVs, CvpB perturbation of
PIKfyve activity stabilizes the autophagy machinery that medi-
ates homotypic fusion between independent CCVs. Solving the
crystal structure of CvpB will provide important insights into the
precise molecular mechanism of this remarkable Coxiella effec-
tor. Four-dimensional microscopy revealed interactions between
PI(3)P-positive endosomes and forming CCVs, which become
enriched in PI(3)P. The unexpected observation of PI(3)P at
CCVs, revealed by the specific probe FYVE, stresses the im-
portance of characterizing the protein as well as lipid composi-
tion of the Coxiella replicative niche to better understand its
biogenesis.
Materials and Methods
Bacterial Strains, Cell Lines, and Growth Conditions. Strains used in this study
are listed in SI Appendix, Table S1. Escherichia coli strains were grown in
Luria–Bertani medium supplemented with ampicillin (100 μg/mL), kanamycin
(50 μg/mL), or chloramphenicol (30 μg/mL) as appropriate. C. burnetii NMII
and transposon mutants were grown in ACCM-2 supplemented with kana-
mycin (340 μg/mL) or chloramphenicol (3 μg/mL) as appropriate in a hu-
midified atmosphere of 5% CO2 and 2.5% O2 at 37 °C. U2OS GFP-2xFYVE
cells were provided by Tassula Proikas-Cezanne (Eberhard Karls University
Tübingen, Tuebingen, Germany). Cells (Vero, HeLa, A431, U2OS, U2OS GFP-
2xFYVE, U2OS mCherry-2xFYVE) were routinely maintained in DMEM con-
taining 10% (vol/vol) FCS in a humidified atmosphere of 5% CO2 at 37 °C.
Cell growth medium was supplemented with 600 μg/mL of Geneticin G418
(Gibco) as appropriate. For PI3-kinase inhibition assay, U2OS GFP-2xFYVE
cells were incubated at 37 °C, 5% CO2, with 50 μM LY294002, 10 mM 3-MA,
or 10 μM Spautin-1 for a minimum of 4 h. Delocalization of GFP-2xFYVE to
the cytoplasm was monitored over time by using an inverted EVOS fluo-
rescence microscope. Where appropriate, after 4 h of treatment with the
aforementioned inhibitors, cells were further incubated with 1 μM YM201636
(always in the presence of the PI3-kinase inhibitors) for 4 h to block PIKfyve
activity. Alternatively, U2OS GFP-2xFYVE cells were incubated with 1 μM
YM201636 alone for 4 h at 37 °C, 5% CO2, to monitor the effects of PIKfyve
inhibition.
Cell Transfection. For the ectopic expression of proteins in mammalian cells,
cells were grown to 60% confluence and transfected with JetPEI cationic
polymer transfection reagent (Polyplus Transfection) according to the
manufacturer’s recommendations. Cells were assayed 12–24 h post trans-
fection. For the generation of U2OS mCherry-2xFYVE, cells were grown to
60–80% confluence before being transfected as described earlier. Cells were
then incubated at 37 °C and 5% CO2 for 24–48 h. For enrichment of U2OS
mCherry-2xFYVE cells, these were maintained in DMEM supplemented with
10% (vol/vol) FCS and containing 600 μg/mL of Geneticin G418. For gene
silencing, U2OS cells were seeded at 2,000 cells per well in black, clear-bot-
tomed, 96-well plates in triplicate and transfected with siRNA oligonucleo-
tides 24 h later by using the RNAiMAX transfection reagent (Thermo Fisher
Scientific) according to the manufacturer’s recommendations. At 24 h post
transfection, cells were challenged with C. burnetii transformants (MOI of
100) and further incubated for 5 d. Cells are then fixed and processed for
immunofluorescence. In parallel, U2OS cells were cultured in six-well plates
and transfected as described earlier. Cell lysates were collected at 24-h in-
tervals during the time course of the experiment, and efficient gene si-
lencing was monitored by Western blot.
Transformation and Axenic Growth of C. burnetii. C. burnetii strains were
transformed with their respective plasmids as described by Martinez et al
(14). For routine culture of C. burnetii strains, 106 GE/mL of bacteria were
inoculated in 4 mL ACCM-2 and allowed to grow for 8 d in a humidified
atmosphere of 5% CO2 and 2.5% O2 at 37 °C. Where needed, 340 μg/mL
kanamycin and/or 3 μg/mL chloramphenicol were added as appropriate to
bacterial cultures. At the indicated time points, bacterial concentrations
were evaluated from 100 μL of cultures by using the PicoGreen (Invitrogen)
assay according to the manufacturer’s instructions.
Immunofluorescence Staining and Microscopy. Cells were fixed in 3% (wt/vol)
paraformaldehyde in PBS solution at room temperature for 30 min or in
methanol/acetone (1:1) at −20 °C for 5 min. Samples were then rinsed in PBS
solution and incubated in blocking solution (0.5% BSA, 50 mM NH4Cl in PBS
solution, pH 7.4). When appropriate, 0.05% saponin was added to the
blocking solution for cell permeabilization. Cells were then incubated with
the primary antibodies diluted in blocking solution for 30 min at room
temperature, rinsed five times in PBS solution, and further incubated for
30 min with the secondary antibodies diluted in the blocking solution.
Fluorescent phalloidin was added to the secondary antibodies to label actin
when needed. To visualize translocated 4xHA-tagged CvpB, cells were fixed
as previously described in 3% (wt/vol) paraformaldehyde in PBS solution.
Then, cells were permeabilized with 0.5% Triton X-100 in PBS solution for
3 min at room temperature. Sample were then rinsed in PBS solution and
incubated with blocking solution [0.1% Triton X-100, 5% (wt/vol) milk in PBS
solution] for 1 h at room temperature. Cells were then incubated with the
anti-HA antibody diluted in the blocking solution for 1h at 37 °C, rinsed five
times in PBS solution, and incubated with the secondary antibody for 1 h at
37 °C. For all conditions, coverslips were mounted by using Prolong Gold
antifade mounting medium supplemented with Hoechst 33258 for DNA
staining. Samples were imaged with a Zeiss Axio Imager Z1 epifluorescence
microscope (Carl Zeiss) connected to a CoolSNAP HQ2 CCD camera (Photo-
metrics). Images were acquired alternatively with 63× or 40× oil immersion
objectives and processed with MetaMorph (Universal Imaging). Alterna-
tively, samples were imaged with an ArrayScan VTI Live epifluorescence
automated microscope (Cellomics) equipped with an ORCA-ER CCD camera
(Hamamatsu). In this case, 25 fields per well were acquired for image anal-
ysis. ImageJ, ICY, and CellProfiler software were used for image analysis
and quantifications.
PI3K Activity Assay. For the analysis of PI3-kinase activity of CvpB, the class III
PI3-kinase kit was used according to the manufacturer’s recommendations
(K-3000; Echelon Biosciences). Recombinant VPS34 (Sigma) was used as
positive control and conditions without enzyme or PI substrate were used as
negative controls. The kinase reaction was performed in 10 mMTris·HCl, pH 7.6,
100 mM NaCl, 1 mM EDTA, 10 mM MnCl2, and 50 μM ATP using 780 nM or
1.56 μM of recombinant protein.
Protein–Lipid Overlay Assay. Purified GST or GST-CvpB was incubated with
PIP Strips and PIP Arrays (Molecular Probes) following the manufacturer’s
recommendations. Briefly, TBS-T/BSA [10 mM Tris·HCl, pH 8, 150 mM NaCl,
0.1% Tween 20, 3% (wt/vol) BSA] was used throughout the assay. PIP Strips
and PIP Arrays were first blocked for 1 h in TBS-T/BSA before being in-
cubated with 1 μg/mL of GST or GST-CvpB at 4 °C overnight. Membranes
were washed three times with TBS-T/BSA and immunoblotted with anti-GST
HRP-conjugated antibodies for 1 h at room temperature. Following three
washes with TBS-T/BSA, the membranes were probed with ECL for signal
detection.
In Vitro Cosedimentation Assays with LUVs. Binding of histidine-tagged CvpB,
CvpB1–500, and CvpB500–809 to LUVs was determined by cosedimentation as-
says. LUVs were made with a mixture of egg PC, brain PS, and PI(3)P at
different molar ratios (100:0:0, 70:30:0, 98:0:2, or 68:30:2). Lipid mixtures
were solubilized in chloroform, dried by evaporation, and resuspended
overnight in a solubilizing buffer (150 mM KCl, 0.5 mM EDTA, 20 mM Hepes,
pH 7.4) and extruded to obtain 200-nm-diameter LUVs. A constant amount
of proteins (8 pmol), full-length CvpB, CvpB1–500, or CvpB500–809 was incubated for
30 min at room temperature with LUVs in a final volume of 100 μL. Samples
were ultracentrifuged for 30 min at 71,000 rpm in a Beckman TLA 100 rotor
at 4 °C. Each sample was then divided into a supernatant (SN; 90 μL), con-
taining unbound proteins, and a pellet (P; 10 μL) containing LUV-bound
proteins. The pellet P was resuspended in 80 μL of solubilizing buffer. A total
of 20 μL of SN or P was analyzed on a 12% SDS/PAGE gel, and proteins were
detected by Western blotting by using an anti-histidine antibody.
Antibodies and reagents, plasmids, and primers used in this study are listed
in SI Appendix. Procedures for plasmid construction, image-based supervised
machine learning, β-lactamase translocation assay, G. mellonella survival
assay, transmission EM, live imaging, protein expression and purification,
and cell fractionation are detailed in SI Appendix.
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Movie S1. U2OS cells were challenged with the Coxiella control transposon mutant Tn1832 (Left), the cvpB::Tn mutant (Middle), or the cvpB::Tn com-
plemented strain (in the presence of aTc; Right) for 3 d before imaging. Images were acquired every 10 min for 32 h in the phase-contrast and GFP channels.
Movie S1
Movie S2. U2OS cells were challenged with the Coxiella cvpB::Tn complemented strain for 3 d in the absence of aTc. Complementation induction was
triggered at the moment of image acquisition. Images were acquired every 10 min for 32 h in the phase-contrast and GFP channels.
Movie S2
Movie S3. U2OS cells expressing mCherry-2xFYVE were challenged with the Coxiella control transposon mutant Tn1832 for 3 d before imaging using a
spinning-disk confocal microscope. Image stacks were acquired every 2 min in the mCherry (white) and GFP channels (green) for 3 h (Left). Surface rendering of
mCherry-2xFYVE–positive compartments and Coxiella colonies was performed with IMARIS software on two ROIs. Surface rendering was superimposed to the
image sequence (Middle) or extracted for easier visualization (Right).
Movie S3
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Movie S4. U2OS cells expressing mCherry-2xFYVE were challenged with the Coxiella complemented mutant cvpB::Tn Comp. for 3 d before imaging by using a
spinning-disk confocal microscope. Image stacks were acquired every 2 min in the mCherry (white) and GFP channels (green) for 40 min (Left). Surface ren-
dering of mCherry-2xFYVE–positive compartments and Coxiella colonies was performed with IMARIS software on two ROIs. Surface rendering was super-
imposed to the image sequence (Middle) or extracted for easier visualization (Right).
Movie S4
Movie S5. U2OS cells expressing mCherry-2xFYVE were challenged with the Coxiellamutant cvpB::Tn for 3 d before imaging by using a spinning-disk confocal
microscope. Image stacks were acquired every 2 min in the mCherry (white) and GFP channels (green) for 40 min (Left). Surface rendering of mCherry-2xFYVE–
positive compartments and Coxiella colonies was performed with IMARIS software on two ROIs. Surface rendering was superimposed to the image sequence
(Middle) or extracted for easier visualization (Right).
Movie S5
Other Supporting Information Files
SI Appendix (PDF)
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 2 
Supporting Methods 3 
Antibodies and reagents 4 
Generation of anti-C. burnetii NMII antibodies in rabbits was performed by Covalab. 5 
Hoechst 33258, anti-mouse and anti-rabbit HRP-conjugated antibodies, Atto-647N 6 
phalloidin, rabbit anti-GST and anti-His HRP-conjugated antibodies, polyclonal anti-7 
LAMP1, polyclonal anti-ATG7, monoclonal anti-HA and polyclonal anti-LC3 8 
antibodies were purchased from Sigma. Polyclonal anti-HA antibody was from Santa 9 
Cruz. Monoclonal anti-β Lactamase (BLAM) antibody was from Pierce. Polyclonal 10 
anti-EEA1 antibody was from EMD Millipore. Polyclonal anti-ATG5 and monoclonal 11 
anti-Rab5 and anti-Rab7 antibodies were from Cell Signaling. Monoclonal anti-LC3 12 
antibody was from Enzo Life Sciences. Monoclonal anti-PIKfyve was from AbD 13 
Serotec. Monoclonal anti-GAPDH was from Life Technologies. Monoclonal anti-14 
GM130 was purchased from BD Biosciences. Mouse and rabbit IgG conjugated to 15 
Alexa Fluor 488, 555 or 647 as well as Prolong Gold antifade mounting reagent were 16 
purchased from Invitrogen. Gold-labelled goat anti-rabbit antibody was purchased 17 
from British Biocell International. Paraformaldehyde, glutaraldehyde, osmic acid, 18 
epon 812, propylene oxide, 300 mesh nickel grids, formvar/carbon-coated nickel 19 
grids, formaldehyde and Lowicryl K4M were purchased from Electron Microscopy 20 
Sciences. LY294002 was purchased from Gibco. YM201636 was from Santa Cruz. 21 
Spautin-1 and 3-Methyladenine (3-MA) were purchased from Sigma. FITC-labelled 22 
Cholera toxin B was purchased from Life Technologies. Active, GST-tagged human 23 
Vps34 was purchased from Sigma. siRNA oligonucleotides were purchased from 24 
Dharmacon. Purified Egg PC, brain PS and 18:1 PI(3)P were from Avanti Polar 25 
Lipids, Inc. 26 
 27 
 28 
Plasmids 29 
Plasmids and primers used in this study are listed in Table 2 and 3, respectively. 30 
DNA sequences were amplified by PCR using Phusion polymerase (New England 31 
Biolabs) and gene-specific primers (Sigma). 32 
 33 
Plasmid design for mammalian cells transfection 34 
In order to generate the plasmid pLVX-mCherry-N2, pLVX-mCherry-C1 was 35 
amplified by inverse PCR using primers PLVX-MluI-NotI-Fw and PLVX-MluI-Rv. 36 
Following digestion with MluI, the vector was ligated to obtain circular pLVX-37 
mCherry-N2. pUC57-Kan containing the eukaryotic codon-optimised sequence of 38 
CvpB (CvpBopt) was obtained from Genscript. CvpBopt was amplified from pUC57-39 
Kan-CvpBopt using primers pairs CvpBopt-AgeI-Fw/CvpBopt-BamHI-Rv and 40 
CvpBopt-MluI/CvpBopt-NotI, and the PCR products were cloned into pcDNA3.1-BirA-41 
HA and pLVX-mCherry-N2, respectively. For cloning of N-terminal truncations of 42 
CvpBopt in pLVX-mCherry-N2, CvpBopt was amplified using forward primers 43 
CvpBopt100-809-MluI-Fw, CvpBopt200-809-MluI-Fw, CvpBopt400-809-MluI-Fw, 44 
CvpBopt500-809-MluI-Fw or CvpBopt600- 809-MluI-Fw and reverse primer CvpBopt-45 
NotI-Rv. For cloning of C-terminal truncation of CvpBopt in pLVX-mCherry-N2, 46 
CvpBopt was amplified using forward primers CvpBopt-MluI-Fw and reverse primers 47 
CvpBopt1-200-NotI-Rv, CvpBopt1-400-NotI-Rv, CvpBopt1-500-NotI-Rv, or 48 
CvpBopt1-600-NotI-Rv. In order to generate pLVX-mCherry-C1-Rab5, Rab5 was 49 
amplified from pCI-Rab5 using primers Rab5-EcoRI-Fw/Rab5-BamHI-Rv and cloned 50 
into pLVX-mCherry-C1. In order to generate pCI-Neo-mCherry-2xFYVE, mCherry-51 
2xFYVE was amplified from pL17mCFywt using the primer pair Cherry-NheI-52 
Fw/PL17-EcoRI-Rv and cloned into pCI-Neo. 53 
 54 
 55 
 56 
Plasmid design for protein expression in Escherichia coli  57 
CvpB was amplified from Coxiella RSA439 NMII genomic DNA using primers CvpB-58 
EcoRI-Fw and CvpB-SalI-Rv and cloned into pGEX4T1 to obtain pGEX4T1-CvpB. To 59 
generate His-tagged CvpB, 1-500 and 500-809 domains of CvpB, the corresponding 60 
DNA sequences were amplified from Coxiella RSA439 NMII genomic DNA using 61 
primer pairs CvpB-EcoRI-Fw/CvpB-SalI-Rv, CvpB-EcoRI-Fw/CvpB1-500-SalI-Rv and 62 
CvpB500-809-EcoRI-Fw/CvpB-SalI-Rv and cloned into pET28a to generate pET28a-63 
CvpB, pET28a-CvpB1-500 and pET28a-CvpB500-809, respectively. 64 
 65 
Plasmid design for secretion assay in C. burnetii 66 
CvpB, CvpBdE and CBU_2052 were amplified from Coxiella RSA439 NMII genomic 67 
DNA using primer pairs CvpB-SalI-Fw/CvpB-SphI-Rv, CvpB-SalI-Fw/ CvpBdE-SphI-68 
Rv and 2052-SalI-Fw/2052-SphI-Rv, respectively. PCR products were cloned into 69 
pJB-CAT-Blam to generate pJB-CAT-Blam-CvpB, pJB-CAT-Blam-CvpBdE and pJB-70 
CAT-Blam-CBU_2052, respectively. 71 
 72 
Plasmid design for CvpB complementation in C. burnetii 73 
TetRA was amplified from pJB-CAT-TetRA using the primer pair TetR-NheI-Fw/TetR-74 
PstI-Rv and cloned into pUCR6K-miniTn7-Kan to generate pUCR6K-miniTn7-Kan-75 
TetRA. cvpB was amplified from Coxiella RSA439 NMII genomic DNA using primers 76 
CvpB-XmaI-Fw/CvpB-EcoRI-Rv and cloned into pRK5-HA to obtain pRK5-HA-CvpB. 77 
HA-CvpB was amplified from pRK5-HA-CvpB using primers HA-PstI-Fw/CvpB-78 
EcoRI-Rv and cloned into pUCR6K-miniTn7-Kan-TetRA to generate pUCR6K-79 
miniTn7-Kan-TetRA-HA-CvpB. The 4xHA tag was amplified from pMMB207C-HAx4 80 
using primers 4xHA-PstI-Fw/4xHA-EcoRI-Rv and cloned into pUCR6K-miniTn7-Kan-81 
TetRA to generate pUCR6K-miniTn7-Kan-TetRA-4xHA. CvpB was amplified from 82 
Coxiella RSA439 NMII genomic DNA using primers CvpB-XmaI-Fw/CvpB-EcoRI-Rv 83 
and cloned into pUCR6K-miniTn7-Kan-TetRA-4xHA to obtain pUCR6K-miniTn7-Kan-84 
TetRA-4xHA-CvpB. 85 
 86 
Image-based supervised machine learning 87 
The identification of transposon insertion leading to multivacuolar phenotypes was 88 
performed using the Classifier package of the CellProfiler Analyst software. Random 89 
images acquired from cells infected either with Coxiella Tn1832 or with the icmS::Tn 90 
mutant were manually sorted into two classification bins (single vacuole and 91 
multivacuolar phenotypes, respectively) to form a training set that is used by 92 
Classifier to generate rules for differentiating among objects in each bin. Classifier 93 
then scored our image database, which included classifying all objects in each 94 
image, count how many object in each class are represented in each image and 95 
computing the enrichment/depletion of each class per image. Enrichment scores are 96 
computed for each sample as the logit area under the ROC curve for the prior versus 97 
the posterior distribution. The prior is computed from the full experiment using a 98 
Dirichlet-Multinomial distribution fit to the groups, and the posterior is computed for 99 
each group independently; that is, each phenotype is treated as positive and all 100 
others as negative for each phenotype in turn. 101 
 102 
Beta-Lactamase translocation assay 103 
For C. burnetii effector translocation assays, cells were cultured in black, clear-104 
bottomed, 96-well plates and infected with the appropriate C. burnetii strain (MOI of 105 
100) for 24 and 48 h. C. burnetii expressing Beta-Lactamase alone were used as 106 
negative control; C. burnetii expressing Beta-Lactamase-tagged CBU_2052 was 107 
used as positive control. Cell monolayers were loaded with the fluorescent substrate 108 
CCF4/AM (LiveBLAzer-FRET B/G loading kit; Invitrogen) in a solution containing 20 109 
mM HEPES, 15 mM probenecid (Sigma) pH 7.3, in HBSS. Cells were incubated in 110 
the dark for 1 h at room temperature and imaged using an EVOS inverted 111 
fluorescence microscope. Images were acquired using DAPI and GFP filter cubes. 112 
The image analysis software CellProfiler was used to segment and identify all cells in 113 
the sample (GFP) and positive cells (DAPI) and to calculate the intensity of 114 
fluorescence in each channel. The percentage of positive cells versus the total 115 
number of cells was then calculated and used to evaluate effector translocation.  116 
 117 
Intracellular replication of Coxiella 118 
Cells were seeded into 96-wells plates (Greiner Bio one) 2 days prior to infection. 119 
Cells were then challenged with C. burnetii strains at an MOI of 100. Bacterial 120 
contact with cells was promoted by centrifugation (10 min, 400 x g, RT) and cells 121 
were incubated in a humidified atmosphere of 5% CO2 at 37°C. Unbound bacteria 122 
were removed after 1h of incubation and cells were further incubated in fresh culture 123 
medium for 7 days. Plates were analyzed at a 24-hours interval using a TECAN 124 
Infinite 200 Pro operated by the Magellan software (TECAN) to monitor the variations 125 
of GFP fluorescence associated with the intracellular growth of Coxiella. 126 
 127 
Transmission electron microscopy 128 
For morphology-EM, cells were fixed in 2.5% glutaraldehyde in 0.1M phosphate 129 
buffer for 1 hour at 4°C, post fixed in 1% osmic acid 1 hour at 4 °C and 0.5% tannic 130 
acid 30min at 4 °C. Cells were then dehydrated and infiltrated with mixes of epon 131 
812/propylene oxide with increasing concentrations of epon before embedding. 132 
Ultrathin sections were cut with a Reichert Ultracut (Leica) ultramicrotome and 133 
collected with 300 mesh nickel grids, stained with 0.2% oolong tea extract 30 min 134 
(OTE, Delta microscopies) and lead citrate 4 min. For immuno-EM, cells were fixed 135 
in 4% formaldehyde and 0.05% glutaraldehyde in 0.1M phosphate buffer for 1 hour 136 
at 4 °C, quenched with 0.05M NH4Cl in 0.1M phosphate buffer for 30 minutes. After 137 
dehydration, cells were infiltrated with mixes of resin (Lowicryl K4M) and ethanol with 138 
increasing concentrations of resin and then embedded. Ultrathin sections were cut 139 
with a Reichert Ultracut (Leica) ultramicrotome and collected with 300 mesh, 140 
formvar/carbon-coated nickel grids. After blocking 20 minutes in Tris buffer (TB; 20 141 
mM Tris-HCl pH 8.2, 1% BSA, 1% goat serum), immunogold labelling was performed 142 
by incubating sections overnight at 4 °C with a rabbit anti-HA antibody diluted 1/50 in 143 
TBS and one hour at room temperature with 20 nm gold labelled goat anti-rabbit 144 
diluted 1/20 in TBS supplemented with 1% teleostean gelatine (Sigma). Finally, the 145 
grids were stained 20 minutes with 2% uranyl acetate. Observations were made on a 146 
Tecnai G2 F20 (200KV , FEG) electron microscope. 147 
 148 
Live imaging 149 
To monitor the formation of C. burnetii parasitophorous vacuoles, U2OS cells 150 
cultured in 6-well plates were challenged with either C. burnetii Tn1832, cvpB::Tn or 151 
the corresponding complemented strain (cvpB::Tn Complemented) at an MOI of 100. 152 
Gene complementation was induced either at the moment of infection or four days 153 
post-infection by adding 400 ng/ml anhydrotetracycline (aTc, Santa Cruz) to the 154 
culture medium. Three days post-infection cells were imaged using an Olympus IX83 155 
inverted microscope equipped with an ANDOR Zyla 4.2 sCMOS camera, a 10X ph 156 
objective in a temperature- and CO2-controlled chamber. Images were acquired 157 
every 10 min over 48 hours. To monitor the dynamics of PI(3)P at the C. burnetii 158 
parasitophorous vacuole, U2OS cells expressing mCherry-2xFYVE cultured in glass-159 
bottomed 35 mm dishes were challenged with C. burnetii, cvpB::Tn or cvpB::Tn 160 
Complemented, at an MOI of 100. Three days post-infection cells were imaged using 161 
an inverted Nikon Ti Eclipse microscope equipped with an ANDOR confocal spinning 162 
disk, an emCCD iXion Ultra camera in a temperature- and CO2-controlled chamber. 163 
Image stacks were acquired every 2 min using a 100X oil immersion objective. In all 164 
cases, ICY software was used for image analysis. 3D reconstruction and surface 165 
rendering were performed using IMARIS. 166 
 167 
Protein expression and purification 168 
Genes cloned into pGEX-4T1 or pET28a vectors were expressed in Escherichia coli 169 
XL1-blue or BL21(DE3) star, respectively. Bacterial cultures were grown at 37°C to 170 
mid-exponential phase (OD600nm=0.5) and induced for 4 h with 0.5 mM IPTG. 171 
Bacteria were harvested by centrifugation, resuspended in GST lysis buffer (20 mM 172 
Tris-HCl pH 8, 300 mM NaCl, 5 % glycerol, complete anti-protease (Roche)) or His 173 
lysis buffer (20 mM Tris-HCl pH 8, 300 mM NaCl, 5 mM imidazole, complete anti-174 
protease (Roche)) and lysed with Bugbuster (Novagen) following the manufacturer’s 175 
recommendations. Lysates were cleared by centrifugation (11 000 g, 20 min, 4°C). 176 
Proteins were purified by gravity flow using glutathione-sepharose (Sigma) for GST-177 
tagged proteins, or HIS Select Nickel affinity resin (Sigma) for histidine-tagged 178 
proteins. GST- and Histidine-tagged proteins were eluted with lysis buffer 179 
supplemented with 25 mM reduced glutathione or 250 mM imidazole, respectively. 180 
 181 
Cell fractionation 182 
U2OS cells grown to 60% confluence in three T75 flasks were infected with C. 183 
burnetii Tn1832, cvpB::Tn or cvpB::Tn Complemented at an MOI of 100, uninfected 184 
cells were used as negative control. After 3 days of infection, cells were washed with 185 
PBS and detached from the flasks using trypsin-EDTA 0.25% and pelleted for 5 min 186 
at 200 x g. Pellets were resuspended in 4 ml of HS buffer (20 mM HEPES pH 7.2, 187 
0.25 M sucrose, 1 mM EDTA and protease inhibitors (Complete, Roche)) and lysed 188 
using a stainless-steel ball homogenizer (9 strokes, 16-μm clearance, Isobiotec). 189 
Homogenates were visually analysed for presence of CCVs using fluorescence and 190 
light microscopy (Evos microscope, Life Technologies). Homogenates were then 191 
spun at 600 x g for 15 min at 4°C and the supernatant (SN) was kept for Western blot 192 
analysis. The pellet was resuspended in 500 μl of HS buffer before being loaded onto 193 
a 12 ml cushion of a 10-35% linear gradient of Histodenz (Sigma) in PBS (15 ml 194 
Falcon tubes). Samples were centrifuged (1 h, 3400 x g, 4°C), separated into 8 195 
fractions of 1.5 ml and analysed by Western blot. 196 
 197 
Galleria mellonella survival assay 198 
Larvae were purchased from Live Foods UK and maintained on wood chips at 14 °C. 199 
Groups of 30 larvae weighing 0.25–0.35 g were injected with 106 GE ml −1 C. burnetii  200 
NMII, Tn1832 or cvpB::Tn into the uppermost right proleg. The larvae were incubated 201 
at 37 °C and survival was monitored at 24 h intervals. Larvae were scored as dead 202 
when they displayed no movement in response to gentle manipulation with a pipette 203 
tip. PBS-injected controls were included and each experiment was carried out in 204 
triplicate. To determine bacterial numbers, at 96 h and 120 h post-infection, three 205 
larvae were placed on ice for 10 min to prevent movement. The bottom 2 mm of each 206 
larva was aseptically removed and haemolymph was drained into a sterile 207 
microcentrifuge tube. Bacterial burden was determined using real-time PCR. C. 208 
burnetii was enumerated using real-time PCR targeting the com1 gene. The Com1 209 
probe was covalently labelled at the 5’ end with the reporter dye FAM and at the 3’ 210 
end with the quencher dye BHQ-1. Primers and probe were purchased (ATDBio). 211 
Chromosomal DNA was extracted by addition of 100 µl sample to 900 µl Instagene 212 
Matrix (Bio-Rad). The Instagene/sample suspension was heated (95 °C ; 15 min), 213 
centrifuged (10000 r.p.m.; 3 min; Eppendorf Microcentifuge model no. 5424) and 214 
supernatant was retained for PCR. PCR cycling conditions comprised 3 min at 95 °C, 215 
30 s at 60 °C, followed by 50 two-step cycles of 15 s at 95 °C and 30 s at 60 °C. 216 
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Supporting Figure Legends  262 
 263 
Supporting Figure 1. Transposon insertion in Coxiella chaperone-encoding 264 
gene icmS leads to a multi-vacuolar phenotype. Vero cells were infected with the 265 
control transposon mutant Tn1832 (top panels) or the icmS::Tn mutant (bottom 266 
panels) and fixed after 5 days of infection. Coxiella colonies were visualised using 267 
transposon-encoded GFP (green); antibodies against LAMP1 (A) or LC3 (B) coupled 268 
to Alexa Fluor 555 (red) were used to visualise CCVs and autophagosomes, 269 
respectively. Scale bars = 5 μm. (C) Cells infected as above were processed for 270 
transmission electron microscopy. Red box and inset indicate the presence of a large 271 
number of bacteria and cellular material inside Tn1832-generated vacuoles. Green 272 
box and inset indicate that icmS::Tn-generated vacuoles are tight-fitting and contain 273 
less bacteria and no cellular material (Insets 1 and 2: details of the vacuolar 274 
membrane). Scale bars = 2 μm.  275 
 276 
Supporting Figure 2. CvpB is a Dot/Icm secreted effector required for optimal 277 
CCV biogenesis and virulence. (A) Schematic representation of the genomic 278 
context of CBU_0021 and sites of transposon insertion of 6 independent isolated 279 
mutants (Tn1146, Tn396, Tn239, Tn170, Tn2579 and Tn2032). The regulatory 280 
element PmrA is represented in red and the predicted E-block motif is indicated in 281 
green. (B) Axenic (ACCM-2) growth of 6 independent cvpB::Tn mutants. Control 282 
transposon mutant Tn1832 (dashed black line) was used as control. Values are 283 
mean ± SD of triplicate experiments. (C) HeLa cells were infected with either Coxiella 284 
Tn1832 (top panels), cvpB ::Tn (middle panels) or the complemented cvpB ::Tn 285 
strain (cvpB::Tn Comp., bottom panels). Six days post-infection, cells were fixed and 286 
stained with anti-LAMP1 (red) and phalloidin (blue). Scale bars = 10 μm. (D) U2OS, 287 
A431, HeLa and Vero cells were challenged either with each cvpB transposon 288 
mutants isolated, with the control Coxiella mutant Tn1832 or with the dotA::Tn 289 
mutant. Intracellular replication of Coxiella was assessed by monitoring the GFP 290 
expressed by the mutants using a microplate reader. Values are mean ± SD from 3 291 
independent experiments.  292 
 293 
Supporting Figure 3. (A) HeLa cells were infected for 24h or 48h with Coxiella NMII 294 
or the dotA::Tn mutant transformed with vectors expressing Beta-Lactamase alone 295 
(BLAM, negative control), BLAM-CBU_2052 (positive control), BLAM-CvpB or BLAM-296 
CvpBΔE-block (CvpBΔE). Secretion of these proteins was probed using the CCF-4 297 
substrate. The average percentage of cells positive for cleaved CCF-4 as compared 298 
to the total number of cells was assessed. Values are mean ± SD from 3 299 
independent experiments. ns = non-significant; *** = P<0.0001 (1-way ANOVA).(B) 300 
Expression of Beta-lactamase (BLAM)-CvpB fusion proteins used for experiments in 301 
Fig. S3A. Bacterial extracts were analysed by Western blot using anti-BLAM (top 302 
panel) and anti-Coxiella NMII (bottom panel) antibodies. (C) Survival chart of Galleria 303 
mellonella larvae infected with either Coxiella NMII (squares), the control mutant 304 
Tn1832 (triangles) or the cvpB ::Tn mutant (circles). PBS-injected larvae were used 305 
as control (inverted triangles). Values are means of three replicates, each with 30 306 
injected larvae per condition. *** = P<0.0001 (cvpB::Tn vs. NMII or Tn1832, Long 307 
Rank Mantel-Cox analysis). (D) Real-time PCR targeting the Coxiella gene com1 308 
was carried out on Galleria mellonella larvae infected with the Coxiella control 309 
transposon mutant Tn1832 or the cvpB::Tn mutant at the indicated time points. * = 310 
P<0.05, ** = P<0.01 (2-way ANOVA, Bonferroni’s multiple comparison test). (E) 311 
cvpB::Tn mutant Tn1146 genomic DNA was either digested with the restriction 312 
enzyme BamHI (Tn1146 BamHI) or left undigested (Tn1146 Undig.) prior to 313 
migration on agarose gel and Southern blot analysis using a fluorescent GFP probe. 314 
The band observed at 8155 bp confirms the unique insertion of the transposon in 315 
cvpB. (F) Expression of HA-tagged CvpB in cvpB::Tn complemented strain in the 316 
presence or absence of 400 ng/ml anhydrotetracycline (aTc). Bacterial extracts were 317 
analysed by Western blot using anti-HA and anti-Coxiella NMII antibodies. (G) 318 
Protein-lipid overlay assay performed with GST alone showed no lipid binding 319 
activity. 320 
 321 
Supporting Figure 4. (A) U2OS cells were co-transfected with pGFP-Lact-C2 322 
(green) and pLVX-CvpB-mCherry (red). CvpB and the PS probe Lact-C2 colocalise 323 
in transfected cells. U2OS cells were transfected either with pLVX-CvpB-mCherry (B) 324 
or pLVX-mCherry (C) and incubated with FITC-labelled Cholera toxin B (CtxB) for 60 325 
min on ice. Cells were then incubated at 37 °C for 30 or 60 min, fixed and labelled 326 
with anti-GM130 coupled to Alexa Fluor 647 (blue). Scale bars = 10 μm. 327 
 328 
Supporting Figure 5. (A) Schematic representation of the CvpB fragments 329 
ectopically-expressed as mCherry fusion proteins (MBD = Membrane-Binding 330 
Domain). (B) U2OS cells were transiently transfected with pLVX-CvpB-mCherry (1-331 
809) or CvpB fragments cloned into pLVX-mCherry (red), fixed and labelled with anti-332 
Rab5 or anti-EEA1 antibodies (green). Systematic analysis of colocalisation between 333 
the CvpB fragments and Rab5- or EEA1-positive vesicles reveals that CvpB has a 334 
MBD spanning from amino acids 1-500, that is necessary for membrane targeting. 335 
Scale bars = 10 μm. 336 
 337 
Supporting Figure 6. (A) U2OS cells were transfected with mCherry-Rab5 and 338 
challenged with either Coxiella Tn1832, the cvpB::Tn mutant or the complemented 339 
strain for 3 days. Coxiella colonies, Rab5-positive vesicles and LAMP1 were 340 
detected using GFP (green), mCherry (red) and an anti-LAMP1 antibody coupled to 341 
Alexa Fluor 647 (blue), respectively. Scale bars = 10 μm. (B) U2OS cells uninfected 342 
or infected for 3 days with either Coxiella Tn1832, the cvpB::Tn mutant or the 343 
complemented strain were lysed and separated into pellet and supernatant (SN) by 344 
low speed centrifugation. The pellet was further separated onto a linear gradient of 345 
Histodenz and the fractions 1 (bottom of the gradient) to 8 (top of the gradient) were 346 
analysed by Western blot using antibodies against GAPDH, Coxiella, Rab7, Rab5 347 
and EEA1. Lack of GAPDH was used as a proxy for efficient cell lysis and the 348 
concomitant presence of Coxiella and Rab7 in fractions was used to identify fractions 349 
enriched in CCVs.  350 
 351 
Supporting Figure 7. U2OS GFP-2xFYVE (green) cells were incubated either with 352 
DMSO (A), the PI 3-kinase inhibitors 3-MA (B) or Spautin-1 (C) for 4 h and 353 
transfected with pLVX-CvpB-mCherry (red) for 12 h (See also corresponding Fig. 354 
5B). Scale bars = 10 μm. 355 
 356 
Supporting Figure 8. (A) U2OS cells were transfected for 2, 4 and 6 days with 357 
either Scramble or PIKfyve-targeting (oligo1, oligo2 or oligo3) siRNA. PIKfyve 358 
expression level was detected by Western blot using an anti-PIKfyve antibody. Anti-359 
GAPDH was used as loading control. All PIKfyve-targeting siRNAs decreased the 360 
expression levels of PIKfyve, oligo2 being the most efficient. (B) U2OS cells were 361 
transfected for 5 days with the indicated siRNAs. Protein expression levels were 362 
detected by Western blot using specific antibodies. Anti-GAPDH was used as loading 363 
control. 364 
  365 
Table 1. List of strains used in this study 366 
Strain Description Origin 
wt Coxiella burnetii Coxiella burnetii RSA 439 Nine Mile II Robert Heinzen 
Coxiella Tn1832 Coxiella burnetii RSA 439 Nine Mile II 
carrying a transposon GFP-CAT between 
CBU_1847b and CBU_1849 
(1) 
Coxiella Tn1146 Coxiella burnetii RSA 439 Nine Mile II 
carrying a transposon GFP-CAT in 
CBU_0021 (cvpB) 
(1) 
Coxiella 
Tn1146comp 
Coxiella burnetii RSA 439 Nine Mile II 
carrying a transposon GFP-CAT in 
CBU_0021 (cvpB) and a transposon 
TetRA-HA-cvpB 
This study 
Coxiella Tn1146 
4xHA-cvpB 
Coxiella burnetii RSA 439 Nine Mile II 
carrying a transposon GFP-CAT in 
CBU_0021 (cvpB) and a transposon 
TetRA-4xHA-cvpB 
This study 
Coxiella Tn2098 Coxiella burnetii RSA 439 Nine Mile II 
carrying a transposon GFP-CAT in 
CBU_1642 (icmS) 
(1) 
Coxiella Tn292 Coxiella burnetii RSA 439 Nine Mile II 
carrying a transposon GFP-CAT in 
CBU_1648 (dotA) 
(1) 
XL-1 Blue E. coli strain used for Ptac-driven 
recombinant protein expression 
Clontech 
BL21(DE3) star E. coli strain used for T7-driven 
recombinant protein expression 
Invitrogen 
 367 
  368 
Table 2. List of plasmids used in this study 369 
Name Description Origin 
pLVX-mCherry-C1 CMV expression vector for N-terminal 
fusion of mCherry 
Clontech 
pCI-Rab5 Encodes human Rab5 Bruno 
Beaumelle 
pLVX-mCherry-C1-Rab5 CMV expression vector expressing 
Rab5 with N-terminal fusion of 
mCherry tag 
This study 
pLVX-mCherry-N2 CMV expression vector for C-terminal 
fusion of mCherry 
This study 
pUC57-Kan-CvpBopt Encodes codon-optimized sequence fo 
cvpB for eukaryotic expression 
(CvpBopt) 
Genscript 
pcDNA3.1-BirA-HA CMV expression vector for C-terminal 
fusion of BirA-HA tag 
Addgene 
pcDNA3.1-CvpBopt-BirA-HA CMV expression vector expressing 
CvpBopt with C-terminal fusion of 
BirA-HA tag 
This study 
pLVX-CvpBopt-mCherry-N2 CMV expression vector expressing 
CvpBopt with C-terminal fusion of 
mCherry tag 
This study 
pLVX-CvpBopt1-200-
mCherry-N2 
CMV expression vector expressing 
CvpBopt1-200 with C-terminal fusion of 
mCherry tag 
This study 
pLVX-CvpBopt1-400-
mCherry-N2 
CMV expression vector expressing 
CvpBopt1-400 with C-terminal fusion of 
mCherry tag 
This study 
pLVX-CvpBopt1-500-
mCherry-N2 
CMV expression vector expressing 
CvpBopt1-500 with C-terminal fusion of 
mCherry tag 
This study 
pLVX-CvpBopt1-600-
mCherry-N2 
CMV expression vector expressing 
CvpBopt1-600 with C-terminal fusion of 
mCherry tag 
This study 
pLVX-CvpBopt100-809-
mCherry-N2 
CMV expression vector expressing 
CvpBopt100-809 with C-terminal fusion of 
mCherry tag 
This study 
pLVX-CvpBopt200-809-
mCherry-N2 
CMV expression vector expressing 
CvpBopt200-809 with C-terminal fusion of 
mCherry tag 
This study 
pLVX-CvpBopt400-809-
mCherry-N2 
CMV expression vector expressing 
CvpBopt400-809 with C-terminal fusion of 
mCherry tag 
This study 
pLVX-CvpBopt500-809-
mCherry-N2 
CMV expression vector expressing 
CvpBopt500-809 with C-terminal fusion of 
mCherry tag 
This study 
pLVX-CvpBopt600-809-
mCherry-N2 
CMV expression vector expressing 
CvpBopt600-809 with C-terminal fusion of 
mCherry tag 
This study 
pGEX-4T1 Ptac expression vector encoding 
glutathione S-transferase (GST) 
GE 
Healthcare 
pGEX-4T1-CvpB Ptac expression vector encoding GST-
CvpB 
This study 
pET28a T7 expression vector Novagen 
pET28a-CvpB T7 expression vector encoding His-
CvpB 
This study 
pET28a-CvpB1-500 T7 expression vector encoding His-
CvpB1-500 
This study 
pET28a-CvpB500-809 T7 expression vector encoding His-
CvpB500-809 
This study 
peGFP-Lactadherin-C2 Encodes GFP-Lactadherin-C2 Addgene 
pGFP-HA-PIKFYVE Encodes GFP-PIKFYVE Assia 
Shisheva 
pCI-Neo CMV expression vector Promega 
pL17mCFywt Encodes mCherry-2xFYVE Kai 
Wengelnik 
pCI-Neo-mCherry-2xFYVE Encodes mCherry-2xFYVE This study 
pGFP-LC3B Encodes GFP-LC3B Martine 
Biard 
pGFP-LC3C Encodes GFP-LC3C Martine 
Biard 
pJB-CAT-Blam Coxiella P1169 expression vector for 
N-terminal fusion of Beta-lactamase 
enzyme 
Robert 
Heinzen 
pJB-CAT-Blam-CvpB Coxiella P1169 expression vector 
expressing CvpB with N-terminal 
fusion of Beta-lactamase enzyme 
This study 
pJB-CAT-Blam-CvpBdE Coxiella P1169 expression vector 
expressing CvpBΔE-block with N-terminal 
fusion of Beta-lactamase enzyme 
This study 
pJB-CAT-Blam-CBU_2052 Coxiella P1169 expression vector 
expressing CBU_2052 with N-terminal 
fusion of Beta-lactamase enzyme 
This study 
pRK5-HA CMV expression vector for N-terminal 
fusion of HA tag 
Gunnar 
Schroeder 
pRK5-HA-CvpB CMV expression vector expressing 
CvpB with N-terminal fusion of HA tag 
This study 
pJB-CAT-TetRA Coxiella anhydrotetracycline-inducible 
expression vector 
Robert 
Heinzen 
pMMB207C-HAx4 Legionella expression vector for N-
terminal fusion of 4xHA 
Gunnar 
Schroeder 
pUCR6K-miniTn7-Kan Contains miniTn7-Kan transposon 
sequence 
Robert 
Heinzen 
pTnS2-P1169TnsA-D Encodes a Tn7 transposase Robert 
Heinzen 
pUCR6K-miniTn7-Kan-TetRA Contains anhydrotetracycline-inducible 
expression cassette in the miniTn7-
This study 
Kan transposon sequence 
pUCR6K-miniTn7-Kan-TetRA-
HA-CvpB 
Contains anhydrotetracycline-inducible 
expression cassette of HA-CvpB in the 
miniTn7-Kan transposon sequence 
This study 
pUCR6K-miniTn7-Kan-TetRA-
4xHA 
Contains anhydrotetracycline-inducible 
expression cassette of 4xHA in the 
miniTn7-Kan transposon sequence 
This study 
pUCR6K-miniTn7-Kan-TetRA-
4xHA-CvpB 
Contains anhydrotetracycline-inducible 
expression cassette of 4xHA-CvpB in 
the miniTn7-Kan transposon sequence 
This study 
 370 
  371 
Table 3. List of primers used in this study 372 
Name Sequence (restriction sites in bold) 
CvpBopt-AgeI-Fw CTAACCGGTTATGAGTCGCCAGCCAAGTCTG 
CvpBopt-BamHI-Rv CTTGGATCCCTTAGTAAAGCTTGCGATTG 
PLVX-MluI-NotI-Fw GTAACGCGTAGCGGCCGCGCCACCATGGTGAGCAAGGGC 
PLVX-MluI-Rv CTGACGCGTGACCGGTAGATCCTCTAGTAGAG 
CvpBopt-MluI-Fw GTTACGCGTATGAGTCGCCAGCCAAG 
CvpBopt-NotI-Rv GAAGCGGCCGCTCTTAGTAAAGCTTGCGATTGGC 
CvpB-EcoRI-Fw GAAGAATTCAGCAGACAGCCATCATTG 
CvpB-SalI-Rv GAAGTCGACTTACTTAGTGAAAGAAGCAATGG 
CvpB1-500-SalI-Rv GAAGTCGACTTAGTTAAGAGCTTTTCTGGATCCAC 
CvpB500-809-
EcoRI-Fw 
GAAGAATTCGGATCCAGAAAAGCTCTTAACG 
CvpB-SalI-Fw CTTGTCGACAGCAGACAGCCATCATTG 
CvpB-SphI-Rv GAAGCATGCTTACTTAGTGAAAGAAGCAATGG 
CvpBdE-SphI-Rv GAAGCATGCTTATGCGTGAGAGTGACTCTG 
2052-SalI-Fw CTTGTCGACCCTAAAAACACAAATCCAGATC 
2052-SphI-Rv GAAGCATGCTTATTTCAAAAAAGCATTTACAAGATC 
CvpBopt1-200-NotI-
Rv GATGCGGCCGCTACACTTTTCCATTGAGGC 
CvpBopt1-400-NotI-
Rv GATGCGGCCGCTGTTTTCCAGCCCATCAATC 
CvpBopt1-500-NotI-
Rv GATGCGGCCGCTATTCAGAGCTTTCCGACTTC 
CvpBopt1-600-NotI-
Rv GAAGCGGCCGCTCAGCAGATTCTGCATTTCG 
CvpBopt100-809-
MluI-Fw GTTACGCGTATGTACAACGAAAACTTCTACAAGAAGC 
CvpBopt200-809-
MluI-Fw GTTACGCGTATGGCCTCAATGGAAAAGTGTC 
CvpBopt400-809-
MluI-Fw GTTACGCGTATGAAGATTGATGGGCTGGAAAAC 
CvpBopt500-809-
MluI-Fw GTTACGCGTATGCTGATGGCCCGACTGTC 
CvpBopt600-809-
MluI-Fw GTTACGCGTATGATCGAAATGCAGAATCTGC 
Cherry-NheI-Fw GAAGCTAGCATGGTGAGCAAGGGCG 
PL17-EcoRI-Rv GTTGAATTCAATGTTCATAATTTTAGCTATTTACATGC 
TetR-NheI-Fw GAGTCAGCTAGCTTAAGACCCACTTTCACATTTAAG  
TetR-PstI-Rv GAACTGCAGCTTTTCTCTATCACTGATAG 
CvpB-XmaI-Fw GTTCCCGGGTCAGCAGACAGCCATCATTG 
CvpB-EcoRI-Rv GAAGAATTCTTACTTAGTGAAAGAAGCAATGG 
HA-PstI-Fw GAACTGCAGATGTACCCATACGATGTTC 
4xHA-PstI-Fw GATCTGCAGATGTCAGAAGGAGATATACATATGTAC 
4xHA-EcoRI-Fw CATGAATTCACGCGTAAATCTTCTCTCATCCGC 
Rab5-EcoRI-Fw CCAGAATTCTATGGCTAGTCGAGGCG 
Rab5-BamHI-Rv GGGGGATCCTTAGTTACTACAACACTGATTCCTG 
Com1-Fw CGACCGAAGCATAAAAGTCAATG 
Com1-Rv ATTTCATCTTGCTCTGCTCTAACAAC 
Com1 Probe TTATGCGCGCTTTCGACTACCATTTCA 
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